Covid restrictions tighten as omicron cases double every two to three days

@article{Torjesen2021CovidRT,
  title={Covid restrictions tighten as omicron cases double every two to three days},
  author={Ingrid Torjesen},
  journal={BMJ},
  year={2021},
  volume={375}
}
The prime minister announced the measures, which include mandatory mask wearing in most public indoor settings, vaccine passports for large capacity events, and working from home, during a televised press conference on 8 December. Although the measures were “irritating,” Boris Johnson said, they were the best way to ensure a “Christmas as close to normal as possible,” given that omicron seemed to bemore transmissible than theprevious delta variant and case numbers were “growing much faster.” 

Protecting the mental health of groups needing NHS care this winter

TLDR
The public waits for signs that the winter will bring a return to familiar stay-at-home orders andudden changes toChristmas plans as the medical community continues to call for more action from the government and the NHS buckles under unsustainable demand.

Interplay Between Risk Perception, Behavior, and COVID-19 Spread

TLDR
This work studied how voluntary health-protective behavior and vaccination willingness impact the long-term dynamics of COVID-19, and analyzed how different levels of mandatory NPIs determine how individuals use their leeway for voluntary actions.

How serious is the Omicron variant? transmissibility, genomics, and responses to COVID-19 vaccines, and ‘Stealth’ Omicron variants

TLDR
The genomics and dissemination of the Omicron variant and the efficiency of vaccines against the O Micron variant are epitomized to prompt the understanding of medical researchers for further investigation in the near future.

Turning point: A new global COVID‐19 wave or a signal of the beginning of the end of the global COVID‐19 pandemic?

TLDR
It is speculated if the virulence of the Omicron variant will diminish as transmissibility increases, thereby signaling the beginning of the end for the global COVID‐19 pandemic.

SARS-CoV-2 seroprevalence in Kaduna State, Nigeria during October/November 2021, following three waves of infection and immediately prior to detection of the Omicron variant

TLDR
The work presented here will inform public health policy and deployment strategies for testing, treatment, and vaccination in Nigeria, and provide a baseline for SARS-CoV-2 seroprevalence in Nigeria immediately prior to the spread of the Omicron variant.

SARS-CoV-2 seroprevalence at urban and rural sites in Kaduna State, Nigeria, during October/November 2021, immediately prior to detection of the Omicron variant

TLDR
This study provides baseline SARS-CoV-2 seroprevalence in Kaduna State, Nigeria, immediately prior to the spread of the Omicron variant, and indicates that in October/November 2021, approximately 56% of the population did not have detectable antibodies, and population subgroups with particularly low serop revalence remain.

Covid-19: Do vaccines work against omicron—and other questions answered

The SARS-CoV-2 omicron variant, first detected in South Africa on 24 November, has now been found in 57 countries. Elisabeth Mahase looks at what we know about it so far, including how well

Forecast of omicron wave time evolution

TLDR
It seems that the German health system can barely cope with the omicron wave avoiding triage decisions, which is about one order of magnitude smaller than the beta fatality rate and total number.

OMICRON: Virology, immunopathogenesis, and laboratory diagnosis

TLDR
An overview of the biological and immunopathological properties of Omicron and its subvariants, its clinical signs and symptoms, Omicon and pediatrics, vaccines against OmicRON, re‐infection with Omicrons, diagnostic approaches and specific challenges of O micron in the successful control and management of the rapid global spread of this variant are provided.

References

SARS-CoV-2 Omicron has extensive but incomplete escape of Pfizer BNT162b2 elicited neutralization and requires ACE2 for infection

TLDR
This work investigated whether Omicron escapes antibody neutralization elicited by the Pfizer BNT162b2 mRNA vaccine and whether the virus still requires binding to the ACE2 receptor to infect cells, and tested the ability of plasma from BNT 162b2 vaccinated study participants to neutralize Omicrons versus ancestral D614G virus in a live virus neutralization assay.